Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have entered into a partnership that would enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany, and allow Boehringer Ingelheim’s clients to use Rentschler’s facilities of process development and intermediate-scale clinical supply production.
Clients would benefit from the combined development and manufacturing know-how and facilities, which would lead to increased flexibility and more customized services. Compatible bioprocessing methods are said to guarantee a seamless project transfer between the companies, which are conveniently located.
Rentschler Biotechnologie, a full-service contract manufacturer focusing on process development and small to medium scale production of mammalian cell-derived biopharmaceuticals, currently operates eight independent GMP lines with fermenter volumes of up to 500 L. A 2,500 L has recently been qualified for future operations. Boehringer Ingelheim, which offers similar services with technologies optimized for large-scale industrial production, is said to run one of the world’s largest biotech facilities with fermenter volumes of up to 15,000 L.
